Session » 3S108 ACR Abstract: RA–Treatments II: Safety (958–963)
- 4:30PM-6:00PM
-
Abstract Number: 963
Long-Term Safety of Tofacitinib up to 9.5 Years: A Comprehensive Integrated Analysis of the RA Clinical Development Program
- 4:30PM-6:00PM
-
Abstract Number: 962
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 6 Years: An Updated Integrated Safety Analysis
- 4:30PM-6:00PM
-
Abstract Number: 961
The Association of Biologic Drug-Levels with Infection Risk: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
- 4:30PM-6:00PM
-
Abstract Number: 959
The Prevalence of Methotrexate Associated Hepatotoxicity in a Multi-Hospital Health System
- 4:30PM-6:00PM
-
Abstract Number: 960
The Risk of Gastrointestinal Perforations Associated with Biologic Disease-Modifying Anti-Rheumatic Drugs Used in Rheumatoid Arthritis: A Nationwide Swedish Cohort Study
- 4:30PM-6:00PM
-
Abstract Number: 958
Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting